Iter-4360dd15-0126-transcript
第 126 轮执行轨迹
→ call search_memory({"limit":8,"query":"4360dd15 PMID 22149876 PMC4713958 abstract erratum corrected sentence original"})【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹
→"}, {"title": "Iter-4360dd15-0094-transcript", "tags": "iteration transcript", "modified": "20260424210844000", "preview": "!! 第 94 轮执行轨迹 → call search_m"}, {"title": "Iter-4360dd15-0090-transcript", "tags": "iteration transcript", "modified": "20260424210019000", "preview": "!! 第 90 轮执行轨迹 → call list_recent({"n":6})
→ call list_by_tag({"limit":10,"tag":"4360dd15"})
【tool:list_recent】
{"ok": true, "items": [{"title": "Iter-4360dd15-0125-reflection", "modified": "20260424221130000", "tags": "iteration reflection"}, {"title": "NEXT_FOCUS", "modified": "20260424221130000", "tags": "pinned focus"}, {"title": "先拿原句再判修订边界", "modified": "20260424221130000", "tags": "lesson erratum evidence-chain"}, {"title": "Iter-4360dd15-0125-transcript", "modified": "20260424221125000", "tags": "iteration transcript"}, {"title": "BOLERO-2 abstract erratum verbatim comparison", "modified": "20260424221118000", "tags": "fact 4360dd15 erratum verification evidence-chain"}, {"title": "Iter-4360dd15-0124-reflection", "modified": "20260424221033000", "tags": "iteration reflection"}]}
【tool:list_by_tag】
{"ok": true, "items": [{"title": "BOLERO-2 abstract erratum verbatim comparison", "modified": "20260424221118000"}, {"title": "BOLERO-2 erratum exact abstract sentence and boundary of correction", "modified": "20260424221021000"}, {"title": "BOLERO-2 erratum corrected abstract sentence", "modified": "20260424220843000"}, {"title": "BOLERO-2 abstract should cite erratum-corrected subgroup wording", "modified": "20260424220656000"}, {"title": "BOLERO-2 erratum scope: subgroup wording only, PFS numerics unchanged", "modified": "20260424220522000"}, {"title": "BOLERO-2 erratum does not change abstract investigator-assessed PFS sentence or bibliographic metadata", "modified": "20260424220413000"}, {"title": "BOLERO-2 PMCID and abstract PFS sentence directly verified from PMC", "modified": "20260424220204000"}, {"title": "BOLERO-2 PMID PMCID DOI confirmed from Europe PMC and PMC", "modified": "20260424220045000"}, {"title": "BOLERO-2 主文数值与 PMID/DOI 的直接抽取（Springer OA + NCBI export）", "modified": "20260424215916000"}, {"title": "BOLERO-2 主要终点具体结果数值（Springer OA）", "modified": "20260424215736000"}]}
→ call read_note({"title":"NEXT_FOCUS"})
【tool:read_note】
{"ok": true, "title": "NEXT_FOCUS", "tags": "pinned focus", "text": "!! 下轮焦点（来自 mission 4360dd15 · Iter-0125）\n\n直接抽取 PMID 22149876 的原始摘要句，并从 PMC4713958 精确截取修订句，逐字比对被改动的唯一边界。"}
→ call pubmed_search({"limit":3,"query":"22149876 BOLERO-2 abstract"})
→ call web_search({"limit":5,"query":"PMC4713958 BOLERO-2 erratum corrected abstract sentence"})
→ call web_search({"limit":5,"query":"PMID 22149876 BOLERO-2 abstract final study results prospectively defined subgroups"})
【tool:pubmed_search】
{"ok": true, "query": "22149876 BOLERO-2 abstract", "results": [{"pmid": "25796760", "title": "[The drug of the month: everolimus (Afinitor) for the treatment of metastatic breast cancer].", "source": "Rev Med Liege", "pubdate": "2014 Sep", "authors": ["Jerusalem G", "Rorive A", "Collignon J"], "url": "https://pubmed.ncbi.nlm.nih.gov/25796760/"}, {"pmid": "24050600", "title": "Everolimus: a new hope for patients with breast cancer.", "source": "Curr Med Res Opin", "pubdate": "2014 Jan", "authors": ["Sendur MA", "Zengin N", "Aksoy S", "Altundag K"], "url": "https://pubmed.ncbi.nlm.nih.gov/24050600/"}]}
【tool:web_search】
{"ok": true, "query": "PMC4713958 BOLERO-2 erratum corrected abstract sentence", "results": [{"title": "Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with ...", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4713958/", "snippet": "In the Abstract , patients with disease recurrence during or within 12 months of completion of adjuvant therapy are grouped with other patient subgroups as being \"prospectively defined\". This subgroup was not included within the prospectively defined patient subgroups for the BOLERO-2 trial."}, {"title": "Erratum to: Everolimus Plus Exemestane in Postmenopausal ... - Europe PMC", "url": "https://europepmc.org/article/PMC/PMC4713958", "snippet": "Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis"}, {"title": "PDF Guide for the Publication of Erratum", "url": "https://www.scielo.org/documents/70/guia_errata_en.pdf", "snippet": "The publication of the erratum does not effectively correct the data in the document; it only informs readers about the corrections. However, since this is a digital publication, some data must mandatorily be corrected in the original document when such corrections involve bibliographic record data that affect bibliographic indexes and DOI ..."}, {"title": "Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with ...", "url": "https://www.academia.edu/126572031/Erratum_to_Everolimus_Plus_Exemestane
【tool:web_search】
{"ok": true, "query": "PMID 22149876 BOLERO-2 abstract final study results prospectively defined subgroups", "results": [{"title": "Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4372651/", "snippet": "As summarized in the final PFS analysis of BOLERO-2 after a median follow-up of 18 months, the effect of everolimus plus exemestane treatment was consistent across subgroups defined by patient characteristics and prior therapy (estimated HR of 0.25 and 0.62, respectively), with everolimus plus exemestane increasing PFS benefits compared with ..."}, {"title": "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast ...", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1109653", "snippet": "In this phase 3, randomized trial, we compared everolimus and exemestane versus exemestane and placebo (randomly assigned in a 2:1 ratio) in 724 patients with hormone-receptor-positive advanced ..."}, {"title": "Abstract P6-04-02: Final progression-free survival analysis of BOLERO-2 ...", "url": "https://aacrjournals.org/cancerres/article/72/24_Supplement/P6-04-02/576954/Abstract-P6-04-02-Final-progression-free-survival", "snippet": "Abstract . Introduction: Treatment options for postmenopausal women with hormone receptor-positive (HR+) breast cancer (BC) who relapse or progress on a nonsteroidal aromatase inhibitor (NSAI) are limited. Interim analyses of the BOLERO-2 trial demonstrated that combi
→ call web_search({"limit":5,"query":"pubmed 22149876 BOLERO-2 Everolimus Plus Exemestane abstract"})
→ call web_search({"limit":5,"query":"22149876 PMID BOLERO-2 PubMed everolimus exemestane"})
【tool:web_search】
{"ok": true, "query": "pubmed 22149876 BOLERO-2 Everolimus Plus Exemestane abstract", "results": [{"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6267855/", "snippet": "The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival (PFS) by more than twofold in patients with hormone-receptor-positive (HR +), HER2-negative advanced breast cancer that recurred or progressed during/after treatment with nonsteroidal aromatase inhibitors ..."}, {"title": "Everolimus plus exemestane for... : Annals of Oncology", "url": "https://www.ovid.com/journals/anonc/fulltext/10.1093/annonc/mdu456~everolimus-plus-exemestane-for-hormone-receptor-positive", "snippet": "The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival (PFS) by more than twofold in patients with hormone-receptor-positive (HR +), HER2-negative advanced breast cancer that recurred or progressed during/after treatment with nonsteroidal aromatase inhibitors ..."}, {"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://www.annalsofoncology.org/article/S0923-7534(19)36905-4/fulltext", "snippet": "The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival (PFS) by more
【tool:web_search】
{"ok": true, "query": "22149876 PMID BOLERO-2 PubMed everolimus exemestane", "results": [{"title": "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast ...", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1109653", "snippet": "In this phase 3, randomized trial, we compared everolimus and exemestane versus exemestane and placebo (randomly assigned in a 2:1 ratio) in 724 patients with hormone-receptor-positive advanced ..."}, {"title": "The BOLERO-2 trial: the addition of everolimus to exemestane ... - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/22764762/", "snippet": "Research has indicated that aberrant signaling through the mTOR pathway is associated with resistance to endocrine therapies. The BOLERO-2 trial examined the effects on progression-free survival of the addition of everolimus to exemestane in a patient population of postmenopausal, hormone receptor-positive, advanced breast cancer."}, {"title": "Everolimus in postmenopausal hormone-receptor-positive advanced breast ...", "url": "https://europepmc.org/article/MED/22149876", "snippet": "The BOLERO-2 study showed that the addition of everolimus to exemestane significantly improves progression-free survival, with observed medians of 6.9 and 2.8 months, corresponding to a 57% reduction in the hazard ratio."}, {"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://www.annalsofoncology.org/article/S0923-7534(19)36905-4/fulltext", "snippet": "The BOLER
→ call web_fetch({"max_chars":8000,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4713958/"})
→ call web_fetch({"max_chars":8000,"url":"https://europepmc.org/article/MED/22149876"})
【tool:web_fetch】
{"ok": true, "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4713958/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis - PMC Skip to main content An official website of the United States government Here's how you know Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. Search Log in Dashboard Publications Account settings Log out Search… Search NCBI Primary site navigation Search Logged in as: Dashboard Publications Account settings Log in Search PMC Full-Text Archive Search in PMC Journal List User Guide PERMALINK Copy As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice Adv Ther . 2014 Sep 11;31:1008–1009. doi: 10.1007/s12325-014-0150-8 Search in PMC Search in PubMed View in NLM Catalog Add to search Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Denise A Yardley De
【tool:web_fetch】
{"ok": true, "url": "https://europepmc.org/article/MED/22149876", "status": 200, "content_type": "text/html;charset=UTF-8", "text": "Europe PMC Europe PMC 1 Sign in | Create an account https://orcid.org https://plus.europepmc.org Europe PMC Menu About About Europe PMC Preprints in Europe PMC Funders Become a funder Governance Roadmap Outreach Tools Tools overview Article status monitor Grant finder External links service RSS feeds About SciLite annotations Annotations submission service Developers Developer resources Articles RESTful API Grants RESTful API API case studies SOAP web service Annotations API OAI service Bulk downloads Developers Forum Support User guide Search syntax guide Contact us Contact us Helpdesk Feedback Twitter Blog Tech blog Developer Forum Europe PMC plus NOTICE: The ORCID Claiming tool has been temporarily disabled, because of technical issues. Please check back in later.", "truncated": false}
→ call web_search({"limit":5,"query":"\"22149876\" \"Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer\""})
【tool:web_search】
{"ok": true, "query": "\"22149876\" \"Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer\"", "results": [{"title": "Efficacy and safety of everolimus plus exemestane in postmenopausal ...", "url": "https://pubmed.ncbi.nlm.nih.gov/29992557/", "snippet": "This trial evaluated the clinical effectiveness of everolimus plus exemestane in postmenopausal women with HR+, HER2- aBC who had progressed on or after an NSAI, but with no restrictions on the time of progression after NSAI, prior chemotherapy for advanced disease or previous exemestane."}, {"title": "Everolimus Plus Exemestane in Postmenopausal Patients with HR", "url": "https://link.springer.com/article/10.1007/s12325-013-0060-1", "snippet": "Methods BOLERO-2 is a phase 3, double-blind, randomized, international trial comparing everolimus (10 mg/day) plus exemestane (25 mg/day) versus placebo plus exemestane in postmenopausal women with HR + advanced BC with recurrence/progression during or after NSAIs."}, {"title": "Everolimus Plus Exemestane in Postmenopausal ... - Semantic Scholar", "url": "https://www.semanticscholar.org/paper/Everolimus-Plus-Exemestane-in-Postmenopausal-with-Yardley-Noguchi/18628012e9bd5552cb865900148821bee522c82c", "snippet": "The addition of everolimus to exemestane markedly prolonged PFS in patients with HR+ advanced BC with disease recurrence/progression following prior NSAIs, and results further support the use ofEverolimus plus exemstane in this patient population. Intro
→ call web_fetch({"max_chars":12000,"url":"https://link.springer.com/article/10.1007/s12325-013-0060-1"})
→ call web_fetch({"max_chars":12000,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4372651/"})
【tool:web_fetch】
{"ok": true, "url": "https://link.springer.com/article/10.1007/s12325-013-0060-1", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis | Advances in Therapy | Springer Nature Link Skip to main content Advertisement Log in Menu Find a journal Publish with us Track your research Search Saved research Cart Home Advances in Therapy Article Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Original Research Open access Published: 25 October 2013 Volume 30 , pages 870–884, ( 2013 ) Cite this article You have full access to this open access article Download PDF Save article View saved research Advances in Therapy Aims and scope Submit manuscript Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Download PDF Denise A. Yardley 1 , Shinzaburo Noguchi 2 , Kathleen I. Pritchard 3 , Howard A. Burris III 1 , José Baselga 4 , Michael Gnant 5 , Gabriel N. Hortobagyi 6 , Mario Campone 7 , Barbara Pistilli 8 , Martine Piccart 9 , Bohuslav Melichar 10 , Katarina Petrakova 11 , Francis P. Arena 12 , Frans Erdkamp 13 , Wael A. Harb 14 , Wentao Feng 15 , Ayelet Cahana 15 , Tetiana Taran 15 , David Lebwohl 15 & … Hope S. Rugo 16 Show authors 24k Accesses 492 Citations 41 Altmetric 2 Mentions Explore al
【tool:web_fetch】
{"ok": true, "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4372651/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.", "truncated": false}
→ call run_python({"code":"from difflib import ndiff\norig = ('Final study results with median 18-month follow-up show that median PFS remained significantly longer with everolimus plus exemestane versus placebo plus exemestane '\n '[investigator review: 7.8 versus 3.2 months, respectively; hazard ratio = 0.45 (95% confidence interval 0.38–0.54); log-rank P < 0.0001; '\n 'central review: 11.0 versus 4)
【tool:run_python】
{"ok": true, "stdout": "PREFIX_END 467\nORIG_CHANGED all prospectively defined subgroups, including patients with visceral metastases, patients with recurrence during or within 12 months of completion of adjuvant therapy\nCORRECT_CHANGED patients with visceral metastases\nSUFFIX_START , and irrespective of age.\n\nDIFF:\n- all\n- prospectively\n- defined\n- subgroups,\n- including\n- patients\n- with\n- recurrence\n- during\n- or\n- within\n- 12\n- months\n- of\n- completion\n- of\n- adjuvant\n- therapy,\n", "stderr": "", "returncode": 0}
→ call write_note({"tags":["4360dd15","fact","erratum verification","evidence-chain"],"text":"!! BOLERO-2 erratum: original abstract sentence vs corrected sentence\n\n!! Source URLs\n- Original article (PMC full text): https://link.springer.com/article/10.1007/s12325-013-0060-1\n- Erratum (PMC4713958): https://pmc.ncbi.nlm.nih.gov/articles/PMC4713958/\n\n!! 原始摘要句（错误版）\n\"Final study results with median 18-month fol)
【tool:write_note】
{"ok": true, "path": "C:\\Users\\yh599\\Documents\\GitHub\\LLM-yh\\Sisyphus\\wiki\\tiddlers\\BOLERO-2_erratum_verbatim_boundary_proof.tid", "title": "BOLERO-2 erratum verbatim boundary proof"}
【assistant】
本轮已完成：把 PMID 22149876 的原始摘要句与 PMC4713958 的 erratum 修订句做了逐字对照，并用 diff 隔离出唯一改动边界。
### 结论
- **被删除的唯一片段**：all prospectively defined subgroups, including patients with recurrence during or within 12 months of completion of adjuvant therapy
- **保留不变的部分**：PFS 数值、HR、CI、P 值全部未改
- **修订后语义**：仅把“prospectively defined subgroups”的范围收窄为
the overall population and in patients with visceral metastases, and irrespective of age
### 证据链
- 原文来源：Springer OA 页面（可抓到完整摘要句）
- 更正来源：PMC4713958 erratum
- 已将对照结果沉淀为记忆条目：
- BOLERO-2 erratum verbatim boundary proof
### 本轮新增可复现方法
- 用 common prefix/suffix + difflib.ndiff 精确定位勘误边界，避免把未改动内容误判为修订内容。
<NEXT_FOCUS>下一轮最值得深入的最窄子问题：确认这处摘要勘误是否对应文章正文中同一措辞在结果段/图注中的“原始用词”与“已更正用词”是否完全一致。 </NEXT_FOCUS>
```